Home    About NDEI   Site Map   FAQ   Contact Us   Feedback   
       Advanced Search    
Home
Slide Library
Literature Alerts
On Demand Activities
Case Studies
Newsletters
Live Events
Treatment Guidelines
Patient Education
Clinical Trials
Product Indications
Calendar Of Events
Glossary
Other Resources
CME Opportunities


Your Online Resource for Diabetes Treatment
Home > Literature Alerts > Insulin Secretion and Insulin Sensitivit...
Printer-Friendly Format
Email this to a friend
Highlight Glossary

Diabetes

Insulin Secretion and Insulin Sensitivity in Relation to Glucose Tolerance: Lessons From the Botnia Study
Tripathy D, Carlsson M, Almgren P, et al.
Diabetes. 2000;49:975-980.

Recently, a new stage in glucose tolerance, impaired fasting glucose (IFG) (fasting plasma glucose level of 6.1– 6.9 mmol/l), was introduced in addition to impaired glucose tolerance (IGT) (2-h glucose level of 7.8– 11.0 mmol/l). It is not clear whether IFG and IGT differ with respect to insulin secretion or sensitivity. To address this question, we estimated insulin secretion (by measuring both insulin levels and the ratio of insulin-to-glucose levels in 30-min intervals) and insulin sensitivity (by using the homeostasis model assessment [HOMA] index) from an oral glucose tolerance test (OGTT) in 5,396 individuals from the Botnia Study who had varying degrees of glucose tolerance. There was poor concordance between IFG and IGT: only 36% (303 of 840) of the subjects with IFG had IGT, whereas 62% (493 of 796) of the subjects with IGT did not have IFG. Compared with subjects with normal glucose tolerance (NGT), subjects with IFG were more insulin resistant (HOMA–insulin resistance [IR] values 2.64 ± 0.08 vs. 1.73 ± 0.03, P < 0.0005), had greater insulin responses during an OGTT (P = 0.0001), had higher waist-to-hip ratios (P < 0.005), had higher triglyceride and total cholesterol concentrations (P < 0.0005), and had lower HDL cholesterol concentrations (P = 0.0001). Compared with subjects with IFG, subjects with IGT had a lower incremental 30-min insulin-to-glucose area during an OGTT (13.8 ± 1.7 vs. 21.7 ± 1.7, P = 0.0008). Compared with subjects with IGT, subjects with mild diabetes (fasting plasma glucose levels <7.8 mmol/l) showed markedly impaired insulin secretion that could no longer compensate for IR and elevated glucose levels. A progressive decline in insulin sensitivity was observed when moving from NGT to IGT and to subjects with diabetes (P < 0.05 for trend), whereas insulin secretion followed an inverted U-shaped form. We conclude that IFG is characterized by basal IR and other features of the metabolic syndrome, whereas subjects with IGT have impaired insulin secretion in relation to glucose concentrations. An absolute decompensation of b-cell function characterizes the transition from IGT to mild diabetes.

The full text of this article is available online.
Registration required.


 Additional Information   Additional Information
ArticleIncidence of Diabetes Mellitus and Impaired Glucose Tolerance in Children and Adolescents Receiving Growth-Hormone Treatment

ArticleIdentification of Persons at High Risk for Type 2 Diabetes Mellitus: Do We Need the Oral Glucose Tolerance Test?

ArticleThe Relative Contributions of Insulin Resistance and Beta-Cell Dysfunction to the Pathophysiology of Type 2 Diabetes

ArticleThe Significance of Impaired Fasting Glucose Versus Impaired Glucose Tolerance: Importance of Insulin Secretion and Resistance

ArticleDetection of Undiagnosed Diabetes and Other Hyperglycemia States: The Atherosclerosis Risk in Communities Study

ArticleLow Insulin Sensitivity (Si = 0) in Diabetic and Nondiabetic Subjects in the Insulin Resistance Atherosclerosis Study. Is it associated with components of the metabolic syndrome and nontraditional risk factors?

ArticleIdentification of Subjects with Insulin Resistance and ß-Cell Dysfunction Using Alternative Definitions of the Metabolic Syndrome

 

Clinical Bridges, Secaucus, NJ
Clinical Bridges is a division of KnowledgePoint360 Group, LLC.
Copyright © 2009 Clinical Bridges. All rights reserved.
National Diabetes Education Initiative, Clinical Bridges, and
KnowledgePoint360 are trademarks of KnowledgePoint360 Group, LLC.
Disclaimer Statement - Privacy Statement